Expertise in
31
conditions

Dr. John Browning

Dermatology | Pediatrics
San Antonio, TX 
Referral may be required
Expertise in
31
conditions
San Antonio, TX 

Overview

John Browning is a Dermatologist and a Pediatrics provider practicing medicine in San Antonio, Texas.

Dr. Browning is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Molluscum Contagiosum, Dominant Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Epidermolysis Bullosa.

He is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 28 clinical trials.

Specialties

Dermatology
Pediatrics

Licenses

Pediatric Dermatology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cambia Health Solutions
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Chinese Community Health
  • HMO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • HMO
  • INSURANCE PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • PPO
HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • MEDICARE MAPD
Sunshine Health
  • EPO
  • HMO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE PDP
Wellcare
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 25 Less Insurance Carriers -

Locations

San Antonio, TX 78257
Other Locations
3320 Oakwell Ct, San Antonio, TX 78218
1763 Medical Way, New Braunfels, TX 78132
1763 Medical Way # B, New Braunfels, TX 78132
San Antonio, TX 78257
3349 S Highway 181 # 6, Kenedy, TX 78119

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drug: GSK1070806
Study Phase: Phase 1
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Orticumab
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: RGN-137
Study Phase: Phase 2
View 9 Less Clinical Trials

48 Total Publications

Clinical and Molecular Effect of the Anti-IL-18 Antibody Aletekitug in Adults With Atopic Dermatitis.
Clinical and Molecular Effect of the Anti-IL-18 Antibody Aletekitug in Adults With Atopic Dermatitis.
Journal: Allergy
Published: July 07, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Eloise Atkinson
Dermatology
Expertise in
26
conditions
Dr. Eloise Atkinson
Dermatology
18540 Sigma Rd, 
San Antonio, TX 
 (8.0 miles away)
210-490-4661
Languages Spoken:
English
See accepted insurances

Eloise Atkinson is a Dermatologist practicing medicine in San Antonio, Texas. Dr. Atkinson is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Liver Spots, Universal Acquired Melanosis, and Warts.

Expertise in
45
conditions
Dr. Mary Altmeyer
Dermatology
Expertise in
45
conditions
Dr. Mary Altmeyer
Dermatology
2620 Mccullough Ave, 
San Antonio, TX 
 (5.0 miles away)
210-490-4661
Languages Spoken:
English
See accepted insurances

Mary Altmeyer is a Dermatologist practicing medicine in San Antonio, Texas. Dr. Altmeyer is highly rated in 45 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Bowen's Disease, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Expertise in
26
conditions
Dr. Lisa Walker
Dermatology
Expertise in
26
conditions
Dr. Lisa Walker
Dermatology
18540 Sigma Rd, 
San Antonio, TX 
 (8.0 miles away)
210-657-9338
Languages Spoken:
English
See accepted insurances

Lisa Walker is a Dermatologist practicing medicine in San Antonio, Texas. Dr. Walker is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Kaposiform Hemangioendothelioma, Fetal Cystic Hygroma, Hemangioendothelioma, and Cerebral Cavernous Malformation.

Frequently Asked Questions about Dr. John Browning

How do I make an appointment with Dr. John Browning?

You can book an appointment with Dr. John Browning by calling their office at 210-337-1050. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Browning a top-rated expert for Molluscum Contagiosum?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Browning is classified as an Elite expert for Molluscum Contagiosum, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Browning specialize in?

While Dr. John Browning is a Dermatology, they have specific expertise in Molluscum Contagiosum, Dominant Dystrophic Epidermolysis Bullosa, and Dowling-Meara Epidermolysis Bullosa Simplex. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. John Browning participate in research or clinical trials?

Yes. Dr. John Browning has published 48 articles and abstracts on conditions like Molluscum Contagiosum. You can view a list of Dr. John Browning's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John Browning accept my insurance?

Dr. John Browning accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 210-337-1050 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Browning's expertise for a condition
ConditionClose
View All 25 Advanced Conditions
View All 91 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile